However, in the whole cohort, the level of apoA-I110−525 was similar in patients with and without coronary atherosclerosis (P = 0.29), since apoA-I110−525 tended to be lower in the presence of atherosclerosis with a borderline significance (P = 0.05) among patients taking LLM. This evidence concerns the gene APOA1 and atherosclerosis.